HOME >> MEDICINE >> NEWS
Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy

A drug developed to relieve one of the major side effects of pain therapy for cancer patients may offer an added benefit for AIDS patients, researchers from the University of Chicago and the Children's Hospital of Philadelphia reported Saturday, October 11, at the 2003 Annual Meeting of the American Society of Anesthesiologists in San Francisco.

Methylnaltrexone (MNTX) was invented to reverse the constipation caused by powerful opioid-based pain relievers such as morphine, OxyContin or Percocet taken by patients with cancer or AIDS. Opiates also appear to increase the ability of HIV to infect certain immune system cells.

This laboratory study found that MNTX blocked increases in HIV entry and replication that occur when immune cells are exposed to therapeutic doses of morphine. In this in-vitro study, very small amounts of methylnaltrexone blocked this process.

"If our studies are borne out in future clinical trials, methylnaltrexone may improve the care of patients who take opioids for pain caused by AIDS," said Jonathan Moss, M.D., Ph.D., professor of anesthesia and critical care at the University of Chicago and director of the study.

Many AIDS patients and more than 500,000 patients with advanced cancer depend on drugs like morphine for pain relief. One side effect of these pain relievers is severe constipation, which can be so distressing that many patients discontinue their pain medication.

Methylnaltrexone was invented to solve this problem by the late Leon Goldberg, a University of Chicago pharmacologist. To help a dying friend with morphine-induced constipation, Goldberg took naltrexone, an established drug that blocks the effects of morphine, and altered it slightly so that it could no longer cross the protective barrier that surrounds the brain.

Consequently, it did not interfere with morphine's effect on pain, which is centered in the brain, but it did block morphine's effects on gut motility, which a
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
14-Oct-2003


Page: 1 2

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug brings new hope to kidney cancer patients
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. New study in Nature demonstrates protection against cell death during heart attack
8. Simple intervention encourages sun protection behaviors
9. Red wine protects the heart
10. Sunflower seed oil can protect low birth weight babies from infection
11. Physical activity linked to protection from Parkinsons disease

Post Your Comments:
(Date:9/4/2015)... ... September 04, 2015 , ... ... taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & ... 2015 symposium are doctors and researchers at the top of their field and ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... in comparison to settlements under the Stark physician self-referral law. “Stark Law ... 17 webinar from Atlantic Information Services, Inc. (AIS), will detail which deals are ...
(Date:9/3/2015)... ... ... AlignLife of Wauwatosa is excited to hold its annual Coat ... adults who don't have the ability to buy a jacket warm enough for the ... Drive to help those in need." , This is AlignLife's third annual Coat Drive. ...
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices is known ... this does not stop at any certain demographic or segment of the population. ... thirty-, fifteen- and ten-second TV commercials. , The closed captioning will allow people with ...
(Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., ... destination of his six-month, 10,000 mile journey from Santiago, Chile to Times Square ... calls the “Connecting Las Americas” project—Max crossed six countries in 168 days on ...
Breaking Medicine News(10 mins):Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6
(Date:9/4/2015)... 04, 2015 Research ... addition of the "Veterinary Pharmaceutical Submissions in ... conference to their offering. This ... of the constituent parts of the application for ... which a marketing authorisation is sought in the ...
(Date:9/4/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercialization of new cancer therapies, today announced its financial ... and provided an overview of recent Company highlights and ... will host a business update conference call and live ...
(Date:9/3/2015)... 3, 2015 Report Details What ... areas are going to grow at the fastest rates? ... 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales at overall world market and ...
Breaking Medicine Technology:Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4
Cached News: